Inclusion Criteria:

          1. ≥18 years old

          2. Patients definitely diagnosed by pathology and/or cytology as advanced breast cancer
             with ER+、Her2-,who failed with standard endocrine therapy.

          3. ECOG PS:0-1,Survival is expected to be greater than 3 months

          4. Main organs function is normal or must meet the following criteria(within past 14
             days) 1) hemoglobin≥90g/L; neutrophils≥1.5 x109/L; Platelets≥100 x109/L
             2)Albumin≥29g/L; total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic
             transaminase(AST) and alanine transaminase(ALT)≤2.5 ULN, and ≤ 5 x ULN with hepatic
             metastasis;serum creatinine ≤1.5 xULN，creatinine clearance >60ml/min;
             Triglyceride≤3.0mmol/L, cholesterol≤7.75mmol/L

        3)Doppler ultrasound evaluation: Left ventricular ejection fraction(LVEF)≥50% 5.Patients
        should be voluntary and sign the informed consent before taking part in the study

        Exclusion Criteria:

          1. Patients with malignant tumors, except for Cured cutaneous basal cell carcinoma and
             cervical carcinoma in situ

          2. Prior treatment with chemotherapy with cytotoxic drugs within 4 weeks, mitomycin C or
             nirtosocarbamide within 8 weeks

          3. Prior treatment with any anti-cancer therapy including hormone therapy
             radioimmunotherapy, molecular targeted therapy, immunotherapy or other biological
             therapy with 2 weeks

          4. Patients treated with other CDK4/6 inhibitors;

          5. Patients with brain metastasis, spinal cord compression, cancerous meningitis, CT or
             MRI examination reminds patients with cerebral or soft meningeal diseases in the
             screening phase;

          6. Previous history of stem cell or bowe marrow transplant;

          7. A variety of factors that affect oral medication (such as inability to swallow,
             gastrointestinal resection, intestinal obstruction, etc.)

          8. Patients with non-healing wounds or fractures, except for bone metastatics with
             pathologic frature

          9. Previous history of uncontrolled cardiovascular disease including: a) Grade 3 or
             higher congestive heart failure (NYHA Classification);b)unstable angina pectoris or
             newly developped angina pectoris within 3months before the trial; c) Myocardial in
             farction or stroke occured within 6 months prior to intiation of trial; d) Arrhythmias
             requiring antiarrhythmic treatment(beta-blocker or digoxin is permitted)

         10. Patients who need to take CYP3A4 inhibitors or inducers from the screening period;

         11. Patients with drug abuse history or unable to get rid of drugs or Patients with mental
             disorders

         12. Patients with the urine protein≥2+, total ammount of 24 hours urinary protein
             determination>1.0 grams;

         13. Patients with hyperactive/venous thrombosis events within 6 months,such as
             cerebrovascular accidents (including temporary ischemic attack), deep venous
             thrombosis and pulmonary embolism

         14. Patients with active hepatitis b or c infection

         15. Patients with immunodeficiency, including HIV positive or other acquired, congenital
             immunodeficiency disease, or organ transplant history;

         16. Patients allergic to TQB3616 or any adjuvant in the capsule

         17. Patients who took part in other trials within 4 weeks;

         18. Patients with concomitant diseases which could seriously endanger themselves or those
             who won't complete the study according to investigators;